Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis ...

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

The update replaces ASTRO’s 2018 recommendations to reflect the growing body of evidence showing that hypofractionated ...

Stage 2 prostate adenocarcinoma is localized, with a nearly 100%, five-year relative survival rate. Diagnosis uses the TNM system, PSA levels and Gleason score to determine cancer stage and risk.

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...

Prostate cancer surgery removes the prostate, but for men with high-risk disease, it doesn't always end the story. Cancer can return, spread, or require additional treatment. Researchers are looking ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...

Prostate cancer is the second most common cancer in US men. Guidelines for screening vary, underscoring the need to engage patients in shared decision-making and counsel them about potential benefits ...

Prostate cancer remains one of the most prevalent malignancies among men worldwide. Effective post-diagnostic management requires repeated staging and longitudinal risk assessment. However, existing ...

Prostate cancer often earns the label “silent killer” because it can develop and progress for years without producing noticeable symptoms. Understanding this timeline becomes crucial for men seeking ...